247 related articles for article (PubMed ID: 26267023)
1. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
2. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
[TBL] [Abstract][Full Text] [Related]
3. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
4. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
5. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
6. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
7. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
Kamoto T
Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
11. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
14. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
15. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Urology; 2016 Oct; 96():171-176. PubMed ID: 27318265
[TBL] [Abstract][Full Text] [Related]
18. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
[TBL] [Abstract][Full Text] [Related]
19. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.
Banefelt J; Liede A; Mesterton J; Stålhammar J; Hernandez RK; Sobocki P; Persson BE
Cancer Epidemiol; 2014 Aug; 38(4):442-7. PubMed ID: 24875326
[TBL] [Abstract][Full Text] [Related]
20. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
